US Democrat Group's Medicare Reform Plan

5 May 1996

The US Progressive Policy Institute, a centrist Democrat think tank, says its Medicare reform plan would save $100 billion over seven years and be more market-based that the GOP version.

The PPI has released a report from health consultants Lewin-VHI showing that its proposal would rely less on government price-setting than the 1995-96 Republican "Medicare Plus" plan, and would include stronger incentives for people to leave traditional Medicare for private-sector alternatives such as managed care.

The PPI plan would also use competitive bidding rather than a government fee scale to find how much the federal Medicare program would pay. Those who chose to remain in traditional fee-for-service Medicare would have to pay part of the additional cost. While Medicare has opened some more health maintenance organizations and private-sector choices for the elderly, it has not been on the scale the Republicans have been lobbying for.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight